$1.05 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
-Total revenue in the last quarter.
-Net income is all revenues minus all expenses including taxes and interest in the last quarter.
$0.00Earnings per share is the amount of net income that is attributed to each single share outstanding.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
-Earnings before interest expenses and taxes in the last quarter.
0The number of full time employees.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Compugen (NASDAQ:CGEN) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports. Other analysts have also rec...Stock Observer, 3 months ago
Equities analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued est...The Olympia Report, 3 months ago
Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. Eleven analysts have rated...Transcript Daily, 3 months ago